IgE‐sensitization predicts threshold but not anaphylaxis during oral food challenges to cow's milk
Authors: Paul J. Turner, Bettina Duca, Sophia A. Chastell, Olaya Alvarez, Raphaëlle Bazire, Marta Vazquez‐Ortiz, Pablo Rodríguez del Río
Journal: Allergy (2021)

There are increasing data relating to predicting the outcomes of oral food challenges (FC) to peanut, specifically severity of reaction and eliciting dose.1 However, data are more limited for other allergens such as cow's milk (CM) protein, particularly in older children and teenagers with persisting allergy to CM. Given that CM is a major cause of severe and even fatal allergic reactions,1 this is a significant knowledge gap. We therefore analysed the predictors of severity and eliciting dose in young people undergoing double-blind placebo-controlled food challenges (DBPCFC) to CM in the SOCMA study (Clinicaltrials.gov NCT02216175). We recruited children and young people aged 6–18 years with a clinical history of CM-allergy, presenting for clinical review in our hospital. Skin prick testing (SPT) of CM and casein was performed according to international guidelines using ALK lancets and commercial extracts (ALK-Abello) with 1% histamine as a positive control, and the mean wheal diameter was noted. Blood samples were collected from participants prior to FC, and specific IgE to CM and casein was measured by ImmunoCAP (ThermoFisher Scientific). The exclusion criteria were medically unfit for challenge (eg high fever or intercurrent illness), acute wheeze or poorly controlled asthma, oral corticosteroids within 14 days of FC, anaphylaxis in 4 weeks prior to FC (to exclude patients in an anergic state) and antihistamines within 5 days of FC. Subjects with a history of prior anaphylaxis were not excluded. The study was approved by the NHS Human Research Authority (reference 18/LO/1070) and the Hospital Infantil Universitario Niño Jesus Ethics Committee (reference R0003/17). Written informed consent was obtained from all participants. 98 participants (median age 10 years) were screened, of whom 93 underwent DBPCFC. The first challenge dose was 0.5 mg CM protein (or tapioca starch as placebo, dissolved in rice "milk" with Nesquik® flavouring) followed by a 60-min observation period. Subsequent doses were given every 20–30 min, according to the following schedule: 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 1000 mg and 3000 mg of CM protein (or placebo), until stopping criteria (PRACTALL) were met. Eliciting dose was defined as the lowest observed adverse effect level (LOAEL) triggering symptoms.2 83 subjects (89%) reacted with objective symptoms at challenge, of whom 16 (19%) had anaphylaxis (WAO 2020 criteria) (Table S1). The median cumulative eliciting dose (cumED) was 143.5 mg (IQR 43.5–443.5 mg) CM protein. Baseline markers of sensitization and other relevant information are shown in Table 1. We did not identify any significant predictors for the occurrence of anaphylaxis at OFC. There was a moderate and significant correlation between specific IgE to CM protein/casein (both SPT and serum IgE) and LOAEL (p < .0001). At multivariate analysis, both SPT and serum IgE to casein were predictive of LOAEL (p = .007 and p = .018, respectively; Table S2). Population dose-distributions were determined as previously described3 using interval-censoring survival analysis (ICSA) approach in R (v4.1.2, survival package v3.2-13). The cumulative eliciting dose predicted to provoke reaction in 5% of the population (ED05) was 2.5 mg (95% CI 1.1–6.0) and 2.7 mg (95% CI 1.2–6.1) CM protein, estimated using log-normal and log-logistic parametric models respectively. The dose distributions are plotted in Figure 1, and are not dissimilar to existing data for LOAEL to CM protein in allergic individuals.4 Predicting reaction threshold and severity are important to improve the management of food allergy; however, the determinants of, and relationship between, these parameters are significant knowledge gaps.1 Identifying robust predictors could enable the reliable risk-stratification of food-allergic individuals. In this series of young people with CM-allergy undergoing DBPCFC — the largest reported in the literature — we did identify any baseline marker that predicted the occurrence of anaphylaxis at challenge, consistent with existing data.1 There is one report of IgE-sensitization being predictive of severity in CM-allergy5; however, the authors included non-reactive patients in their analysis that significantly skewed the analyses, resulting in misleading conclusions.6 IgE-sensitization in our cohort, particularly to casein, was predictive of LOAEL. Including an assessment of IgE-sensitisation to casein may therefore be of clinical utility when evaluating patients with CM-allergy in the clinical setting. We thank our study participants and research colleagues for their support. We also thank Dr Benjamin Remington for his advice on the interval-censoring survival analysis. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: grants from Jon Moulton Charity Trust, UK Medical Research Council, Spanish Society of Allergology and Clinical Immunology and Spanish Society of Paediatric Allergology, Asthma and Clinical Immunology. PJT reports additional grants from UK Medical Research Council, NIHR/Imperial BRC and UK Food Standards Agency during the conduct of the study; personal fees from UK Food Standards Agency, DBV Technologies, Aimmune Therapeutics, Allergenis and ILSI Europe, outside the submitted work. RB reports funding from the Health Research Fund of Carlos III Health Institute (Spain) and honoraria for lectures from LETI Pharma. MVO reports additional research funding from the Health Research Fund of Carlos III Health Institute (Spain), and the FPIES Foundation. PRR reports funding from the Health Research Fund of Carlos III Health Institute, Foundation for Biomedical Research of the Niño Jesus University Children's Hospital, and reports honoraria for consultancy and/or advisory board and/or lectures from ALK-Abello, FAES Pharma, LETI Pharma, Merck, Aimmune Therapeutics, Allergy Therapeutics, MEDA Pharma and NovartisDC. All other authors declare no competing interests. PJT and MVO conceived the study, and drafted the study protocol together with PRR. PJT and PRR are the lead investigators for the study. PJT, BD, OA, RB and PRR were responsible for recruitment and clinical assessments. PJT, BD, RB and SAC were responsible for data analysis and SAC and PJT undertook statistical analyses. PJT drafted this manuscript which was then reviewed and approved by all authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.